Pyrotinib for HER2-positive metastatic breast cancer: a systematic review and meta-analysis.

ABSTRACT:

Background

Human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer patients continue to progress despite multiple anti-HER2-targeted treatments. A number of studies have found that Pyrotinib, a small-molecule pan-ErbB receptor tyrosine kinase inhibitor (TKI), is effective in treating patients with HER2-positive metastatic breast cancer. This systematic review and meta-analysis aimed to evaluate the efficacy and safety of Pyrotinib in the treatment of HER2-positive metastatic breast cancer.

Methods

PubMed, Embase, Web of Science, and Cochrane Library databases were searched until February 2022. Research on HER2-positive metastatic breast cancer being treated with Pyrotinib in any line of therapy was included, both prospective and retrospective. Stati

SUBMITTER: Hu W 

PROVIDER: S-EPMC10007886 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature